ClinicalTrials.gg
Active, not recruitingNCT04565665Updated Oct 5, 2026

Study of Cord Blood Derived Mesenchymal Stem Cells for Treatment of Moderate, Severe or Critical Pneumonia

A Phase 1/2 interventional study of Best Practice and Mesenchymal Stem Cell in COVID-19 Infection, COVID-19-Associated Acute Respiratory Distress Syndrome and Hematopoietic and Lymphoid Cell Neoplasm, sponsored by M.D. Anderson Cancer Center. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by M.D. Anderson Cancer Center · Phase 1/2, Interventional, and Treatment

How we know

Updated Oct 5, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
65
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in COVID-19 by M.D. Anderson Cancer Center — 5 open to participants now, 10 under way, none of them phase 3. COVID-19 · M.D. Anderson Cancer Center.

Started
2020
with 10 others
Phase 1/2
Only one
of the 14
Registered
11th of 14
by date

Among the 14 studies in COVID-19 by M.D. Anderson Cancer Center, this one is one of 11 that started in 2020, is the only one in phase 1/2, and was the 11th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

5 of the 14 studies in COVID-19 by M.D. Anderson Cancer Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in COVID-19 by M.D. Anderson Cancer Center, or all of them as a file.
02

Study summary

This is a phase I trial followed by a phase II randomized trial. The purpose of phase I study is the feasibility of treating patients with acute respiratory distress syndrome (ARDS) related to COVID-19 infection (COVID-19) with cord blood-derived mesenchymal stem cells (MSC). The purpose of the phase II trial is to compare the effect of MSC with standard of care in these patients. MSCs are a type of stem cells that can be taken from umbilical cord blood and grown into many different cell types that can be used to treat cancer and other diseases. The MSCs being used for infusion in this trial are collected from healthy, unrelated donors and are stored and grown in a laboratory. Giving MSC infusions may help control the symptoms of COVID-19 related ARDS.

Read the detailed description

PRIMARY OBJECTIVE:

1. To assess the safety of administering cord blood derived mesenchymal stem cell (CB-MSC) infusions for treatment of moderate, severe or critical pneumonia.

SECONDARY OBJECTIVES:

  1. In the group of participants who present intubated on ventilator support, assess the proportion that are able to be successfully extubated.
  2. In the group of participants who present requiring supplemental oxygen but otherwise breathing without assistance, assess the rate of progression to intubation.
  3. Estimate the survival rate at day 30 post treatment separately by group.
  4. Determine the treatment effect on clinical parameters, oxygenation and respiratory parameters:

    • Resolution of fever
    • Changes in oxygen demand (increased oxygen saturation at similar FiO2 or decreased FiO2 requirement)
    • Progression to mechanical ventilation
    • Length of Mechanical ventilation
    • Decrease in PEEP in intubated participants
    • Decrease in FiO2 in intubated participants
  5. Determine the treatment effect on laboratory markers:

    • Complete blood count
    • CRP
    • Ferritin
    • D Dimer
    • Procalcitonin
    • Cytokine levels
  6. Estimate hospitalization and ICU stay.
  7. Report on study related adverse events.

OUTLINE:

Currently not shipping cells outside of MD Anderson Cancer Center in Houston.

PILOT STUDY: Patients receive MSCs intravenously (IV) over 1-2 hours on day 1. participants may receive a second infusion of MSCs within 7 days after the first infusion per physician discretion.

PHASE II STUDY: Patients are randomized to 1 of 2 arms.

ARM I: Patients receive MSCs IV over 1-2 hours on day 1. Patients may receive a second infusion of MSCs within 7 days after the first infusion per physician discretion.

ARM II: Patients receive standard of care.

After completion of study treatment, patients are followed up at days 7, 14, 30, 60, and months 6 and 12.

03

Conditions studied

  • COVID-19 Infection
  • COVID-19-Associated Acute Respiratory Distress Syndrome
  • Hematopoietic and Lymphoid Cell Neoplasm
  • Malignant Solid Neoplasm
  • Symptomatic COVID-19 Infection Laboratory-Confirmed
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age greater than or equal 18 years.
  2. Participants with chest x-ray findings concerning for pneumonia from any cause, with clinical signs suggestive of at least moderate illness such as respiratory rate >20 breaths per minute or with oxygen saturation less than 93% on room air**
  3. Participants with COVID-19 associated pneumonia must meet baseline categorization of Moderate, Severe or Critical COVID-19 per FDA Guidance for Industry COVID-19: Developing Drugs and Biologics Products for Treatment or Prevention, February 2021.
  4. Negative pregnancy test in a woman with defined as not for 12 months or no previous surgical sterilization.
  5. Participant or legally authorized representative consent. Participants with diminished mental capacity may be allowed on to enroll on the study.
  6. Because of the nature of COVID-19, participants enrolled on this study with COVID-19 associated pneumonia may have been previously enrolled in other IND trials for their cancer diagnosis or for COVID-19. These enrollments will not exclude them from enrollment to this study.

Exclusion criteria

Exclusion Criteria:

  • Moribund participants not expected to survive up to 48 hours
  • Participants with severe chronic liver disease (Childs-Pugh score > 10)
  • Pregnant and/or lactating women
  • Participants on extracorporeal membrane oxygenation
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
65 participants (estimated)

Study arms

  • Experimental
    Phase II Arm I (mesenchymal stem cells)

    Patients receive MSCs as in the Pilot study.

    Biological: Mesenchymal Stem Cell

  • Active comparator
    Phase II Arm II (standard of care)

    Patients receive standard of care.

    Other: Best Practice

  • Experimental
    Pilot study (mesenchymal stem cells)

    Patients receive MSCs IV over 1-2 hours on day 1. Patients may receive a second infusion of MSCs within 7 days after the first infusion per physician discretion.

    Biological: Mesenchymal Stem Cell

Interventions

  • OtherBest Practice

    Receive standard of care

    Also known as: standard of care, standard therapy

  • Given IV

    Also known as: Mesenchymal Progenitor Cell, MPC

06

What researchers measure

Primary outcomes

  1. Incidence of composite serious adverse events (Phase I)

    Serious adverse events with be comprised of grade 3 or 4 graft versus host disease or death and will be estimated and reported overall and by group, along with 95% confidence intervals.

    Time frame: Within 30 days of the first mesenchymal stem cell (MSC) infusion

  2. Patients alive without grade 3, 4 infusional toxicity (Phase II)

    Time frame: At day 30 post MSC infusion

  3. Patients alive with grade 3 or 4 infusional toxicity (Phase II)

    Time frame: At day 30 post MSC infusion

  4. Patients not alive (Phase II)

    Time frame: At day 30 post MSC infusion

Secondary outcomes

  1. Proportion of successfully extubated patients who present intubated on ventilator support (Phase I)

    Will be estimated and reported with 95% confidence intervals.

    Time frame: Up to day 30 post MSC infusion

  2. Rate of successful progression to intubation in patients who require supplemental oxygen but who are otherwise able to breathe without assistance (Phase I)

    Will be estimated and reported with 95% confidence intervals.

    Time frame: Up to day 30 post MSC infusion

  3. Overall survival rate (Phase I)

    Will be estimated and reported with 95% confidence intervals.

    Time frame: At day 30 post MSC infusion

  4. Survival rate in patients who present intubated on ventilator support (Phase I)

    Will be estimated and reported with 95% confidence intervals.

    Time frame: At day 30 post MSC infusion

  5. Survival rate in patients who require supplemental oxygen but who are otherwise able to breathe without assistance (Phase I)

    Will be estimated and reported with 95% confidence intervals.

    Time frame: At day 30 post MSC infusion

  6. Clinical parameters (Phase I)

    The effect of MSCs on clinical parameters will be assessed. Continuous clinical parameters will be summarized by means, medians, standard deviations, ranges, and quartiles. Categorical parameters will be summarized by frequency tables.

    Time frame: Up to day 30 post MSC infusion

  7. Oxygenation parameters (Phase I)

    The effect of MSCs on oxygenation parameters will be assessed. Continuous oxygenation parameters will be summarized by means, medians, standard deviations, ranges, and quartiles. Categorical parameters will be summarized by frequency tables.

    Time frame: Up to day 30 post MSC infusion

  8. Respiratory parameters (Phase I)

    The effect of MSCs on respiratory parameters will be assessed. Continuous respiratory parameters will be summarized by means, medians, standard deviations, ranges, and quartiles. Categorical parameters will be summarized by frequency tables.

    Time frame: Up to day 30 post MSC infusion

  9. Laboratory markers (Phase I)

    The effect of MSCs on laboratory markers will be assessed. Continuous laboratory parameters will be summarized by means, medians, standard deviations, ranges, and quartiles. Categorical parameters will be summarized by frequency tables.

    Time frame: Up to day 30 post MSC infusion

  10. Hospitalization stay (Phase I)

    Time frame: Up to day 30 post MSC infusion

  11. Intensive care unit stay (Phase I)

    Time frame: Up to day 30 post MSC infusion

  12. Incidence of infusion-related adverse events (Phase I)

    All grades of infusion-related adverse events will be summarized by grade and type.

    Time frame: Up to day 30 post MSC infusion

07

Study locations

1 site
08

References and documents

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2020 (actual). Primary completion is estimated for Oct 2027, 87 months after the start.

Of 107 non-industry phase 1/2 interventional studies under COVID-19, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 21. This study's planned 87 months is above that.

Counting every sponsor, half of 187 studies reached it within 11 months; a quarter within 4 and three quarters within 20.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 5, 2026: primary completion Oct 2026 → Oct 2027 and completion Oct 2026 → Oct 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2020
First posted
Sep 25, 2020
StartActual
Jul 29, 2020
Primary completionEst.
Oct 30, 2027was Oct 2026
CompletionEst.
Oct 30, 2027was Oct 2026
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Oct 30, 2026→Oct 30, 2027
Oct 5, 2026
Study completion
Oct 30, 2026→Oct 30, 2027
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    Primary completion Oct 30, 2026→Oct 30, 2027
    Study completion Oct 30, 2026→Oct 30, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04565665
Responsible party
Sponsor
First posted
Sep 25, 2020
Start date
Jul 29, 2020
Primary completion
Oct 30, 2027 (estimated)
Completion
Oct 30, 2027 (estimated)
Last update
Oct 5, 2026

Study contacts

Amanda Olson
principal investigator · M.D. Anderson Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mesenchymal Stem Cell

Start the discussion